Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 7733

1.

Acute Sarcomeric M-Line Disease Associated With ATP Synthase Subunit α Autoantibodies in Ankylosing Spondylitis.

Guglielmi V, Vattemi G, Cecconi D, Fracasso G, Marini M, Tomelleri G.

J Neuropathol Exp Neurol. 2018 Sep 12. doi: 10.1093/jnen/nly079. [Epub ahead of print]

PMID:
30215745
2.

Targeted therapies for pediatric psoriasis.

Schwartz G, Paller AS.

Semin Cutan Med Surg. 2018 Sep;37(3):167-172. doi: 10.12788/j.sder.2018.048.

PMID:
30215634
3.

TNF inhibitors for psoriasis.

Chima M, Lebwohl M.

Semin Cutan Med Surg. 2018 Sep;37(3):134-142. doi: 10.12788/j.sder.2018.039.

PMID:
30215629
4.

Focus on biosimilar etanercept - bioequivalence and interchangeability.

Cantini F, Benucci M.

Biologics. 2018 Aug 30;12:87-95. doi: 10.2147/BTT.S126854. eCollection 2018. Review.

5.

Advances in the treatment of uveitis in patients with spondyloarthritis - is it the time for biologic therapy?

Mitulescu TC, Trandafir M, Dimăncescu MG, Ciuluvică RC, Popescu V, Predețeanu D, Istrate S, Voinea LM.

Rom J Ophthalmol. 2018 Apr-Jun;62(2):114-122. Review.

6.
7.

Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update [Internet].

Donahue KE, Gartlehner G, Schulman ER, Jonas B, Coker-Schwimmer E, Patel SV, Weber RP, Lohr KN, Bann C, Viswanathan M.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Jul.

8.

Maintenance of low disease activity and remission with etanercept-disease-modifying antirheumatic drug (DMARD) combination therapy compared with treatment with DMARDs alone in Latin American patients with active rheumatoid arthritis: Subset analysis of a randomized trial.

Zerbini CAF, Abud-Mendoza C, Mendez-Patarroyo P, De Angelo Andrade M, Pedersen R, Vlahos B, Borlenghi CE.

Medicine (Baltimore). 2018 Sep;97(36):e11989. doi: 10.1097/MD.0000000000011989.

9.

Etanercept for Ankylosing Spondylitis With Coexisting Demyelinating Myelitis.

Ye C, Geng Z, Li S, Yu F.

Am J Ther. 2018 Aug 8. doi: 10.1097/MJT.0000000000000835. [Epub ahead of print] No abstract available.

PMID:
30199382
10.

Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: An integrated analysis from 11 clinical trials.

Langley RG, Kimball AB, Nakagawa H, Xu W, Pangallo B, Osuntokun OO, Agada N, Reich K.

J Eur Acad Dermatol Venereol. 2018 Sep 10. doi: 10.1111/jdv.15242. [Epub ahead of print]

PMID:
30198588
11.

Reparative radiological changes of hip joint after TNF inhibitors in ankylosing spondylitis.

Maatallah K, Mahmoud I, Belghali S, Ben Abdelghani K, Saidane O, Bouajina E, Laatar A, Tekaya R, Abdelmoula L.

Caspian J Intern Med. 2018 Summer;9(3):303-305. doi: 10.22088/cjim.9.3.303.

12.

Cost evolution of biological agents for the treatment of spondyloarthritis in a tertiary hospital: influential factors in price.

González-Fernández M, Villamañán E, Jiménez-Nácher I, Moreno F, Plasencia C, Gaya F, Herrero A, Balsa A.

Int J Clin Pharm. 2018 Sep 8. doi: 10.1007/s11096-018-0703-z. [Epub ahead of print]

PMID:
30196515
13.

Etanercept biosimilar SB4 in the treatment of chronic plaque psoriasis. Data from the Psobiosimilars registry.

Gisondi P, Bianchi L, Calzavara-Pinton P, Conti A, Chiricozzi A, Fimiani M, Pellegrino M, Giunta A, Prignano F, Tiberio R, Venturini M, Girolomoni G.

Br J Dermatol. 2018 Sep 5. doi: 10.1111/bjd.17133. [Epub ahead of print]

PMID:
30187461
14.

Assessing the Role of DNA Methylation-Derived Neutrophil-to-Lymphocyte Ratio in Rheumatoid Arthritis.

Ambatipudi S, Sharp GC, Clarke SLN, Plant D, Tobias JH, Evans DM, Barton A, Relton CL.

J Immunol Res. 2018 Aug 14;2018:2624981. doi: 10.1155/2018/2624981. eCollection 2018.

15.

Bone tumors developed in patients with juvenile inflammatory arthritis after anti-TNFα therapy.

Chi H, Teng J, Yang C, Su Y.

Immunotherapy. 2018 Sep;10(12):1033-1039. doi: 10.2217/imt-2018-0022.

PMID:
30185135
16.

Tocilizumab and the risk for cardiovascular disease: a direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients.

Xie F, Yun H, Levitan EB, Muntner P, Curtis JR.

Arthritis Care Res (Hoboken). 2018 Sep 3. doi: 10.1002/acr.23737. [Epub ahead of print]

PMID:
30175897
17.

The use of etanercept for treatment of toxic epidermal necrolysis when toxic shock syndrome is in the differential.

So N, Leavitt E, Aleshin M, Worswick S.

Dermatol Ther. 2018 Sep 2:e12684. doi: 10.1111/dth.12684. [Epub ahead of print]

PMID:
30175438
18.

Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review.

Murage MJ, Tongbram V, Feldman SR, Malatestinic WN, Larmore CJ, Muram TM, Burge RT, Bay C, Johnson N, Clifford S, Araujo AB.

Patient Prefer Adherence. 2018 Aug 21;12:1483-1503. doi: 10.2147/PPA.S167508. eCollection 2018. Review.

19.

Tumor necrosis factor-α mediated pain hypersensitivity through Ret receptor in resiniferatoxin neuropathy.

Lu SC, Chang YS, Kan HW, Hsieh YL.

Kaohsiung J Med Sci. 2018 Sep;34(9):494-502. doi: 10.1016/j.kjms.2018.04.008.

20.

Retention rates of adalimumab, etanercept, and infliximab as first- or second-line biotherapies for spondyloarthritis patients in daily practice in Auvergne (France).

Soubrier M, Pereira B, Fan A, Frayssac T, Couderc M, Malochet-Guinamand S, Mathieu S, Tatar Z, Tournadre A, Dubost JJ.

Int J Rheum Dis. 2018 Aug 30. doi: 10.1111/1756-185X.13375. [Epub ahead of print]

PMID:
30168265

Supplemental Content

Loading ...
Support Center